Key Points {#FPar1}
==========

Terizidone is not completely metabolised into cycloserine in patients with drug-resistant tuberculosis.Cycloserine and terizidone cannot be used interchangeably.Cycloserine and terizidone exposure may be a predisposing factor to the development of jaundice in patients with drug-resistant tuberculosis.

Introduction {#Sec1}
============

Drug-resistant tuberculosis remains a public health crisis, and treatment success continues to be low, at 55% worldwide \[[@CR1]\]. Cycloserine is among the recommended group C second-line drugs for treatment of drug-resistant tuberculosis \[[@CR2]\]. One of its advantages is that it does not share cross-resistance with other anti-tuberculosis drugs in the regimen, although it is associated with neurological side effects \[[@CR3]\]. Its antimycobacterial bacteriostatic effect is achieved through inhibition of the enzymes [d]{.smallcaps}-alanine ligase and alanine racemase, which are both essential for the biosynthesis of peptidoglycan, a bacterial cell wall component \[[@CR4]\]. The susceptibility breakpoint is 64 µg/mL, and efficacy is driven by the percentage of time the plasma concentration is above the minimum inhibitory concentration. Nevertheless, the doses likely to achieve bactericidal effect in patients could be neurotoxic, as they are high \[[@CR5]\].

Terizidone, which is a condensation product of two molecules of cycloserine joined by a terephthalaldehyde moiety, is also part of the recommended group C second-line drugs for treatment of drug-resistant tuberculosis \[[@CR2], [@CR6]\]. The metabolism of terizidone has not been characterised. However, it is thought to convert into cycloserine and para-phthalate, likely by hydrolysis of imine groups pre-systemically \[[@CR7], [@CR8]\]. Terephthalaldehyde in humans has been shown to undergo quick metabolism into terephalic acid, which is a more stable metabolite and readily excreted in urine \[[@CR9]\]. However, the enzymes involved in these metabolic processes are not known. The in vivo metabolism of cycloserine, a structural analogue of amino acid [d]{.smallcaps}-alanine \[[@CR6]\], has not been characterised in humans. Meanwhile, in vitro studies show that [d]{.smallcaps}- or [l]{.smallcaps}-cycloserine in the presence of alanine racemase undergo racemisation followed by transamination to form a stable isoxazole by irreversible tautomerisation of the intermediate substrate, ketimine \[[@CR10]\].

In patients with drug-resistant tuberculosis, a dose of 250--500 mg of cycloserine administered orally twice daily is slowly absorbed, with an absorption rate constant of 0.135 h^−1^, and reaches the average maximum plasma concentration of 22 µg/mL within 4 h \[[@CR11]\]. It is widely distributed to most body fluids (bile, synovial fluid, breast milk, sputum) and tissues (lymphatic tissues and lungs) and crosses the placenta, with the apparent distribution of 10.5 L. Cycloserine apparent clearance is 1.38 L/h. It is primarily excreted in urine, with 50 and 70% excreted unchanged in 12 and 24 h, respectively. The elimination half-life is 5.27 h. The between-subject variation in apparent clearance and distribution volume is 22.3 and 35.1%, respectively \[[@CR11], [@CR12]\].

Treatment of drug-resistant tuberculosis with a multidrug regimen consisting of cycloserine/terizidone and other second-line drugs is associated with adverse reactions \[[@CR13]\]. Hepatotoxicity, nephrotoxicity and hypokalaemia are the most possible life-threatening adverse reactions that require alteration of the drug regimen or temporal withdraw \[[@CR14]\]. Furthermore, mortality is high when hepatotoxicity is accompanied by jaundice, encephalopathy and ascites \[[@CR15]\].

Cycloserine and terizidone are considered equivalent, and doses are currently used interchangeably \[[@CR7], [@CR8]\]. Owing to the unavailability of bioequivalence or mass balance studies of terizidone, the equivalence of dosing has not yet been established \[[@CR8]\]. The objective of this study was to determine the average amount of cycloserine that results from the metabolism of terizidone in patients with drug-resistant tuberculosis. We also assessed the potential effect of cycloserine and terizidone exposure on the incidence of hepatotoxicity or nephrotoxicity in these patients.

Methods {#Sec2}
=======

The details of the study design, including the study population, drug administration, ethics, inclusion and exclusion criteria, and population pharmacokinetic modelling, have been described elsewhere \[[@CR16]\]. Briefly, this was a prospective clinical study of patients admitted for intensive phase treatment of drug-resistant tuberculosis. They were taking 500--750 mg of terizidone once daily, and other second-line anti-tuberculosis drugs (ethionamide, pyrazinamide, moxifloxacin, ethambutol, isoniazid and kanamycin) were administered according to the local treatment guideline \[[@CR17]\]. Blood for pharmacokinetics study was sampled at baseline and 0.5, 1, 2, 3, 3.5, 4, 8, 16 and 24 h after drug administration. Separate blood samples were also drawn for liver \[total bilirubin, conjugated bilirubin, unconjugated bilirubin, albumin, alanine aminotransferase (ALT), aspartate transaminase (AST)\] and renal function markers (serum creatinine). Estimated glomerular filtration rate (eGFR) \[[@CR18]\] and creatinine clearance (CrCL) \[[@CR19]\] were calculated, and demographic information including HIV status was obtained from each patient.

Determination of Cycloserine and Terizidone in Plasma {#Sec3}
-----------------------------------------------------

Cycloserine concentration in plasma was determined using an ultra-performance liquid chromatography tandem mass spectrometry method. Methanol was used to extract cycloserine and propranolol (internal standard) from plasma by a protein precipitation method. Acidified acetonitrile with 0.1% formic acid was used as the mobile phase, and chromatographic separation was achieved on a Phenomenex PFP reversed phase column. The lower limit of quantification and limit of detection were 0.01 μg/mL and 0.004 μg/mL, respectively. The average intra-day precision was 10.2%, while inter-day was 7.3%. Accuracy ranged between 98.7 and 117.3%, and the coefficient of determination was 0.9994. Cycloserine was stable after three freeze--thaw cycles, and extraction efficiency was in the range 88.7--91.2% \[[@CR20]\]. Terizidone was analysed using a high-performance liquid chromatography with UV detector (HPLC-UV) method. The within- and between-run accuracy was in the range 99.7--112.7% and 100.5--107.4%, respectively. The intra- and inter-day precision, measured as percentage relative standard deviation, ranged between 0.35 and 9.4% and 1.48 and 6.79%, respectively. The lower limit of quantification was 3.125 µg/mL, while the limit of detection was 0.78 µg/mL. The coefficient of determination value ranged between 0.9988 and 0.9999, and calibration curves were linear \[[@CR21]\].

Pharmacokinetic Modelling {#Sec4}
-------------------------

The concentration--time profiles of terizidone and its metabolite cycloserine were jointly modelled using non-linear mixed effects implemented in Monolix 2018R1 software \[[@CR22]\]. The final joint model without covariates was used to estimate the biotransformation rate constant (ktr) describing the metabolism of terizidone into cycloserine and cycloserine clearance (CLm/F). The model and the validation details have been described elsewhere \[[@CR16]\].

Calculation of the Amount of Cycloserine and Other Pharmacokinetic Parameters {#Sec5}
-----------------------------------------------------------------------------

The following formulae were coded and added to the Monolix MLXTRAN model script of the final joint model for the computation of parameters. The amount of cycloserine was calculated as shown in Eq. ([1](#Equ1){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Dose}} = {\text{AUC}} \times {\text{Clm/F,}}$$\end{document}$$where dose is the amount of cycloserine, AUC is the area under the concentration--time profile of cycloserine from 0 to 24 h, and CLm/F is the apparent clearance of cycloserine.

The AUC was calculated by integrating the concentration from 0 to 24 h according to Eq. ([2](#Equ2){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{AUC}} = \mathop \int \limits_{0}^{24} C(t){\text{d}}t,$$\end{document}$$where *C* is cycloserine concentration.

Cycloserine half-life was calculated according to Eq. ([3](#Equ3){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Cycloserine}}\,{\text{half}}\,{\text{life}} = \frac{{{ \ln }(2)}}{\text{ke}},$$\end{document}$$where $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{ke}} = ({\text{Clm/F}})/10.5.$$\end{document}$

The distribution volume of cycloserine was fixed to a literature value of 10.5 L \[[@CR11]\] when estimating CLm/F. This was done in order to overcome the non-identifiability parameter problem encountered in parent--metabolite pharmacokinetic models of orally administered drugs \[[@CR23]\].

The biotransformation half-life was calculated as shown in Eq. ([4](#Equ4){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Biotransformation}}\,{\text{half-life}} = \frac{\ln (2)}{\text{ktr}}.$$\end{document}$$

The peak (*C*~max~) and trough (*C*~min~) concentrations were obtained from the observed data for both cycloserine and terizidone concentration--time profiles. The individual predicted values for terizidone clearance due to biotransformation (CLtm/F) and other routes (CLto/F) were computed in Monolix and extracted from the output file.

Calculation of Binding Affinity of Unconjugated Bilirubin to Albumin and AST/ALT Ratio {#Sec6}
--------------------------------------------------------------------------------------

The strength of unconjugated bilirubin binding to albumin was calculated according to Eq. ([5](#Equ5){ref-type=""}) \[[@CR24]\]:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$K_{\text{af}} = \frac{{{\text{TB}} - {\text{UB}}}}{{{\text{UB}} \times {\text{albumin}} - {\text{TB}} + {\text{UB}}}},$$\end{document}$$where *K*~af~ is the binding affinity, with the units L/µmol, and TB and UB are total bilirubin and unconjugated bilirubin, respectively. The AST/ALT ratio \[[@CR25]\], a marker reflecting alterations in hepatic function, was calculated by dividing the AST value by the ALT value for each patient.

Statistical Analysis {#Sec7}
--------------------

Mann--Whitney *U* test was performed to determine differences in the demographic information stratified by HIV status. We performed Spearman's correlations between hepatic or renal function (eGFR/CrCL) markers and pharmacokinetic parameters (*C*~min~, *C*~max~, CLm/F, CLtm/F and CLto/F). This was done in order to determine whether a statistically significant linear relationship existed, as cycloserine or terizidone could bind to albumin or affect the binding affinity of unconjugated bilirubin to albumin. Furthermore, cycloserine concentration may be affected by alterations in hepatic or renal function. If the correlations were significant, linear stepwise regression analysis was performed in order to determine if pharmacokinetic parameters were significantly predicting hepatic or renal function markers. A two-tailed *p* value of ≤ 0.05 was considered statistically significant. The analysis was performed in the R version 3.5.3 statistical environment \[[@CR26]\].

Results {#Sec8}
=======

Thirty-nine drug-resistant tuberculosis patients (20 females and 19 males) participated in this study. Out of the seven patients with comorbidities, three had cryptococcal meningitis, while each of the remaining four had deep venous thrombosis, hyperlipidaemia, gastric acid or epilepsy. Thirty-eight out of 39 patients took a daily dose of 750 mg terizidone, while one patient took 500 mg. Table [1](#Tab1){ref-type="table"} shows the summary of demographic information. The HIV-infected patients had significantly lower albumin than their HIV-uninfected counterparts (30 vs. 35.5 g/L; *p* = 0.041). However, the rest of the demographic variables were similar in HIV-infected and HIV-uninfected groups.Table 1Patients' demographic informationVariablesHIV infected (*n *= 27)^a^HIV uninfected (*n* = 12)^a^*P* valueAge (years)31 (17--44)34 (20--56)0.46Weight (kg)51.4 (32.4--64)50 (39.8--71)0.69BMI (kg/m^2^)18.5 (12.4--23.5)17.9 (15--26.1)0.8Albumin (g/L)30 (15--45)35.5 (26--48)0.041\*ALT (IU/L)11 (4--46)10.5 (4--23)0.47AST (IU/L)36 (20--109)26.6 (17--76)0.053Conjugated bilirubin (µmol/L)1 (1--8)1 (1--9)0.86Unconjugated bilirubin (µmol/L)5 (1--17)7 (2--11)0.42Total bilirubin (µmol/L)6 (2--24)8 (3--20)0.69AST/ALT ratio3.2 (0.8--8.7)2.7 (1.9--5.9)0.39*K*~af~ (L/µmol)146 (70.9--710)128 (75.5--377)0.84CrCL (mL/min)86.4 (34.4--128)77.8 (55.4--113)0.41eGFR (mL/min/1.73 m^2^)118 (46--228)104 (74.9--192)0.57*ALT* alanine aminotransferase, *AST* aspartate transaminase, *BMI* body mass index, *CrCL* creatinine clearance, *eGFR* estimated glomerular filtration rate, *K*~*af*~ binding affinity\*Statistically significant^a^The values in the column are reported as median and range

Amount of Cycloserine and Pharmacokinetic Parameters {#Sec9}
----------------------------------------------------

The summary of the calculated amount of cycloserine or dose resulting from terizidone metabolism and the values for pharmacokinetic parameters is shown in Table [2](#Tab2){ref-type="table"}. There was wide variation in cycloserine dose and also in the pharmacokinetic parameters, except for cycloserine half-life, for which the variation was relatively narrow. Table [3](#Tab3){ref-type="table"} shows the summary of terizidone pharmacokinetic parameters.Table 2Cycloserine dose and pharmacokinetic parametersParameterMedian (range)Cycloserine dose (mg)51.6 (0.64--374)*C*~max~ (µmol/L)28.6 (0.49--69.4)*C*~min~ (µmol/L)9.1 (0.15--36.3)AUC (µmol h/L)201 (3.07--983)Biotransformation half-life (h)22.6 (10.2--216)CLm/F (L/h)2.6 (0.64--21)Cycloserine half-life (h)2.78 (0.34--11.3)*AUC* area under the curve, *CLm/F* apparent clearance of cycloserine, *C*~*max*~ peak concentration, *C*~*min*~ trough concentrationTable 3Pharmacokinetic parameters for terizidoneParameterMedian (range)*C*~min~ (µmol/L)88 (14.3--307)*C*~max~ (µmol/L)247 (61--583)CLtm/F (L/h)0.29 (0.05--1.14)CLto/F (L/h)0.11 (0.035--0.31)*CLtm/F* terizidone clearance due to biotransformation, *CLto/F* terizidone clearance via other routes, *C*~*max*~ peak concentration, *C*~*min*~ trough concentration

Correlations Between Hepatic Function Markers and Pharmacokinetic Parameters of Cycloserine and Terizidone {#Sec10}
----------------------------------------------------------------------------------------------------------

Significant positive correlations existed between AST, ALT, conjugated bilirubin, *K*~af~ and cycloserine pharmacokinetic parameters (*C*~min~, *C*~max~ or CLm/F), as shown in Table [4](#Tab4){ref-type="table"}. There was significant negative correlation between AST/ALT ratio and CLm/F (*p* = 0.016). Meanwhile, there was no significant correlation between albumin or unconjugated bilirubin and the pharmacokinetic parameters (*p* \> 0.05). Similarly, no significant correlations existed between renal function markers (CrCL and eGFR) and CLm/F (*p* \> 0.05). Significant positive correlations existed between terizidone *C*~max~ and conjugated or unconjugated bilirubin (*p* = 0.038 and 0.02, respectively), as shown in Table [5](#Tab5){ref-type="table"}.Table 4Correlations between cycloserine pharmacokinetic parameters and liver function markers*C*~min~ (µmol/L)*C*~max~ (µmol/L)CLm/F (L/h)AST (IU/L)*r* = 0.26*r* = 0.34\**r* = − 0.06ALT (IU/L)*r* = 0.15*r* = 0.11*r* = 0.35\*Conjugated bilirubin (µmol/L)*r* = 0.36\**r* = 0.47\*\**r* = 0.07Unconjugated bilirubin (µmol/L)*r* = 0.12*r* = 0.15*r* = 0.09*K*~af~ (L/µmol)*r* = 0.38\**r* = 0.46\*\**r* = − 0.02AST/ALT ratio*r* = 0.1*r* = 0.2*r* = − 0.38\**ALT* alanine aminotransferase, *AST* aspartate transaminase, *CLm/F* apparent clearance of cycloserine, *C*~*max*~ peak concentration, *C*~*min*~ trough concentration, *K*~*af*~ binding affinity, *r* Spearman's *ρ* correlation coefficient\**p* \< 0.05, \*\**p* \< 0.001Table 5Correlations between terizidone pharmacokinetic parameters and liver function markers*C*~min~ (µmol/L)*C*~max~ (µmol/L)CLtm/F (L/h)CLto/F (L/h)AST (IU/L)*r* = 0.06*r* = 0.15*r* = − 0.13*r* = − 0.06ALT (IU/L)*r* = 0.16*r* = 0.14*r* = 0.1*r* = 0.05Conjugated bilirubin (µmol/L)*r* = 0.22*r* = 0.33\**r* = 0.13*r* = 0.06Unconjugated bilirubin (µmol/L)*r* = 0.25*r* = 0.37\**r* = − 0.01*r* = − 0.01*K*~af~ (L/µmol)*r* = 0.07*r* = 0.1*r* = − 0.07*r* = − 0.15AST/ALT ratio*r* = − 0.1*r* = − 0.06*r* = 0.16*r* = − 0.17*ALT* alanine aminotransferase, *AST* aspartate transaminase, *CLtm/F* terizidone clearance due to biotransformation, *CLto/F* terizidone clearance via other routes, *C*~*max*~ peak concentration, *C*~*min*~ trough concentration, *K*~*af*~ binding affinity, *r* Spearman's *ρ* correlation coefficient\**p* \< 0.05

Pharmacokinetic Parameters Predictive of Hepatic Function Markers {#Sec11}
-----------------------------------------------------------------

The cycloserine *C*~max~ was found to be a significant predictor of both conjugated bilirubin and *K*~af~, as shown by regression plots b and c of Fig. [1](#Fig1){ref-type="fig"}. The associations were in such a way that an increase in *C*~max~ resulted in a significant increase in conjugated bilirubin and *K*~af~ (plot b, *β* = 0.06, *R*^2^ = 22% and *p* = 0.003; plot c, *β* = 2.3, *R*^2^ = 10.1% and *p* = 0.048). *C*~min~ could not significantly predict *K*~af~ in the regression analysis, although a significant correlation existed between *C*~min~ and *K*~af~ in correlation analysis. Meanwhile, increase in *C*~min~ was significantly associated with an increase in conjugated bilirubin (plot a, *β* = 0.1, *R*^2^ = 10.6% and *p* = 0.044). The CLm/F significantly predicted AST/ALT ratio, as shown in plot d of Fig. [1](#Fig1){ref-type="fig"}. Increase in CLm/F was significantly associated with a decrease in AST/ALT ratio (*β* = − 0.2, *R*^2^ = 21% and *p* = 0.003). Terizidone *C*~max~ significantly predicted concentration of conjugated bilirubin (*β* = 0.008, *R*^2^ = 14.2% and *p* = 0.018) as well as unconjugated bilirubin (*β* = 0.012, *R*^2^ = 11.4% and *p* = 0.035). The regression plot is shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 1Regression plots of cycloserine pharmacokinetic parameters predictive of conjugated bilirubin, AST/ALT ratio and *K*~af~. *ALT* alanine aminotransferase, *AST* aspartate transaminase, *K*~*af*~ binding affinity, *CLm/F* apparent clearance of cycloserine, *C*~*max*~ peak concentration, *C*~*min*~ trough concentrationFig. 2Regression plots of terizidone pharmacokinetic parameters predictive of conjugated and unconjugated bilirubin. *C*~*max*~ peak concentration

Discussion {#Sec12}
==========

This study aimed to determine the amount of cycloserine that results from the metabolism of terizidone and the relationship between cycloserine exposure parameters and hepatic or renal function markers in patients receiving treatment for drug-resistant tuberculosis. There appears to be no studies in the literature that have quantified the amount of cycloserine as a terizidone metabolite in drug-resistant tuberculosis patients. Terizidone is thought to undergo complete hydrolysis into cycloserine pre-systemically \[[@CR7]\]. Since one mole of terizidone has two moles of cycloserine and a mole of terephthalaldehyde moiety, it is expected for a 750-mg daily dose of terizidone to produce 507 mg of cycloserine, with an assumption that bioavailability is near 100%. In the current study, the median dose of cycloserine produced from a 750-mg dose of terizidone was 51.6 mg, which was lower than expected. This observation clearly suggests that terizidone is not completely hydrolysed to cycloserine pre-systemically. Furthermore, terizidone was detected systemically over a period of 24 h after its administration, and on average, only 29% of the total dose was metabolised to cycloserine \[[@CR16]\]. The clinical implication of this finding in the current study is that cycloserine and terizidone should not be used interchangeably, as exposure parameters (*C*~max~, *C*~min~ and AUC) may be significantly lower in patients taking terizidone than those taking cycloserine. Owing to the low amount of cycloserine produced from terizidone, dose optimisation or therapeutic drug monitoring, contrary to what some authors imply \[[@CR27]\], should be based on terizidone and not cycloserine concentration. Additionally, in patients treated with terizidone, Court et al. \[[@CR28]\] reported higher cycloserine *C*~max~ than in the current study. The difference could have been that in the Court et al. study \[[@CR28]\], there were patients who had renal insufficiency, which could have led to accumulation of cycloserine, as it primarily undergoes renal elimination \[[@CR6]\]. Furthermore, the bioavailability and biotransformation rate of terizidone into cycloserine in the current study could have been lower than in the Court et al. \[[@CR28]\] study. We cannot overlook the possibility of pharmacokinetic interactions with co-administered drugs in the current study.

Bilirubin, a pigment derived from the breakdown of haemoglobin, increases in blood because of an imbalance between its production and excretion. Since unconjugated bilirubin is not water soluble, it is bound to albumin and transported to the liver, where it is made soluble or conjugated with glucuronic acid and subsequently undergoes biliary excretion into the gastrointestinal tract \[[@CR29]\]. Increased serum levels of conjugated bilirubin are an indication of hepatic dysfunction or liver disease, clinically manifested as jaundice \[[@CR25]\]. In the current study, cycloserine *C*~min~ and *C*~max~ as well as terizidone *C*~max~ were significantly associated with increased concentration of conjugated bilirubin.

Although the concentration of conjugated bilirubin in most of the patients was within the normal range, this observation implies that high plasma cycloserine or terizidone concentrations may be associated with hyperbilirubinaemia in some patients.

Unconjugated bilirubin is insoluble in water and hence cannot be excreted via the kidney. It is instead bound to albumin and transported to the liver for conjugation. Increased serum levels of unconjugated bilirubin indicate that there is an accumulation in the bloodstream due to haemolysis, which may be caused by haemolytic anaemia, hepatocellular dysfunction (e.g. hepatitis) and cirrhosis in which the excretory function of the hepatocytes is impaired \[[@CR25]\]. Some drugs have been shown to compete with unconjugated bilirubin for binding to albumin, which leads to increased concentration of unconjugated bilirubin and causes encephalopathy in neonates \[[@CR30]--[@CR33]\]. Therefore, the binding affinity of unconjugated bilirubin to albumin is of clinical importance. Cycloserine *C*~max~ in the current study was associated with increased *K*~af~, while *C*~min~ results were insignificant. This means that high cycloserine concentrations improve the binding affinity of unconjugated bilirubin to albumin, which is potentially a desired characteristic in bilirubin metabolism. The observed relationship between *K*~af~ and *C*~max~ may also imply that cycloserine is less bound to albumin.

The AST/ALT ratio is a non-invasive diagnostic index used to predict liver cirrhosis or fibrosis, and a value higher than 1 is indicative of non-alcoholic fatty liver disease \[[@CR34], [@CR35]\]. Cycloserine is primarily renally cleared, with 70% excreted unchanged \[[@CR12]\], while the other portion is metabolised in the liver. However, the enzymes specifically involved in the catabolism of cycloserine in vivo are not known. In the current study, higher CLm/F was significantly associated with low AST/ALT ratio. Additionally, the median value of the AST/ALT ratio was more than 2. This was an obvious indication that liver disease affects hepatic function, which leads to low activity or production of cycloserine-metabolising enzymes and eventually results in low CLm/F. Meanwhile, the non-correlation between CLm/F and CrCL or eGFR in the current study was unexpected, as cycloserine is also cleared via the renal route. This observation could suggest a possibility of more cycloserine undergoing active tubular secretion than glomerular filtration, as seen in other drugs \[[@CR36]\].

This study has some limitations to consider. In vitro drug plasma binding studies were not performed due to ethical issues as we were supposed to use drug-free human plasma. Cycloserine metabolites were not measured in plasma; this could have helped to determine the rate of cycloserine metabolism in vivo. Furthermore, cycloserine was not measured in patients' urine for determination of the fraction of the dose that is excreted unchanged. We only measured cycloserine and terizidone in plasma. Since patients were on a multidrug treatment regimen, other anti-tuberculosis drugs could have shown similar results as cycloserine and terizidone. The study, however, is important as it gives an insight into how cycloserine and terizidone exposure might affect hepatic function. This can guide the clinical decision regarding whether or not to withdraw terizidone in the case of hepatotoxicity.

Conclusions {#Sec13}
===========

In conclusion, the amount of cycloserine resulting from the metabolism of terizidone in drug-resistant tuberculosis patients was lower than expected. High concentrations of cycloserine could potentially favour bilirubin disposition, albeit be a predisposing factor to the development of jaundice in drug-resistant tuberculosis patients taking terizidone. Cycloserine clearance is reduced in hepatic dysfunction.
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